- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
Vaxon completes enrolment in Phase IIb trial of Vx-001 in NSCLC
16 March 2016 • Author: Victoria White
Vaxon has announced the completion of enrolment for its Phase IIb trial of Vx-001 in non-small-cell lung cancer (NSCLC).
Vx-001 is a therapeutic cancer vaccine based on proprietary antigens known as optimised cryptic tumour peptides.
A total of 220 patients with metastatic NSCLC have now been enrolled in this Phase IIb trial across 70 European trial centres. The primary endpoint is to assess the benefit of Vx-001 versus placebo on overall survival. Final trial results are expected in the fourth quarter of 2016.
An average of one in six patients were selected after meeting three criteria: expression of HLA-A2, TERT-expressing tumours and non-progression of cancer after first line chemotherapy. Over four months, participants received six doses of the Vx-001 vaccine or the placebo, then one dose every three months.
Vx-001 is the only vaccine to use optimised cryptic peptides
Vx-001 is the first vaccine to use optimised cryptic peptides and is the only such vaccine in development. Optimised cryptic peptides are universal tumour peptides that, while normally undetected by the immune system, have been modified to optimise their presentation to the immune system so as to induce a powerful anti-tumour immune response.
Vaxon’s optimised cryptic peptides, like neo-antigen vaccines, avoid the problem of immune tolerance and are strongly immunogenic. Unlike neo-antigen vaccines, Vaxon’s optimised cryptic peptides need not be individualised; instead, they have the potential to treat tumours across a broad range of patients, since optimized cryptic peptides are essentially ‘universal neo-antigens’.
“This immuno-oncology trial is one of the biggest of its kind to be carried out by a small biotech company,” said Kostas Kosmatopoulos, Vaxon’s CEO and founder. “Finalising the study has been extremely satisfying for Vaxon Biotech as it has surpassed many of the expectations for a company of our size. It is a strong sign for the market.”
If the results are positive, a large phase 3 study for the same indication will be launched across the European Union and in the United States in 2017.
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) EUROGENTEC F.P.S. Food and Pharma Systems Srl IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics